Equillium, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel immunomodulatory therapies for the treatment of severe autoimmune and inflammatory disorders. Founded in 2014 and headquartered in San Diego, California, Equillium applies its proprietary immunology platform to advance a pipeline of antibody‐based product candidates designed to modulate T cell activity and restore immune balance.
The company’s lead candidate, itolizumab (EQ001), is a humanized anti‐CD6 monoclonal antibody originally licensed from Biocon and engineered to minimize immune response while targeting T cell activation. Itolizumab is being evaluated in pivotal trials for acute graft‐versus‐host disease following hematopoietic stem cell transplantation. Equillium’s second program, EQ002, is engineered to address chronic inflammatory conditions such as psoriasis and lupus by selectively inhibiting proinflammatory cytokines without broadly suppressing the immune system.
Equillium conducts multinational clinical studies across North America, Europe and Asia, collaborating with academic medical centers and regulatory agencies to examine safety, efficacy and biomarker-driven patient selection. The company’s research and development facilities in the United States are complemented by manufacturing partnerships that support both preclinical and clinical stage production under Good Manufacturing Practice (GMP) standards.
Under the leadership of President and Chief Executive Officer Roger Pomerantz and Chief Medical Officer Dr. Lavanya Ambati, Equillium has expanded its management team with seasoned professionals in immunology, clinical operations and regulatory affairs. The organization remains committed to translating scientific innovation into transformative therapies for patients suffering from life‐threatening immune‐mediated diseases.
AI Generated. May Contain Errors.
Free EQ Stock Alerts